FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176037701> ?p ?o ?g. }

• W3176037701 endingPage "3630" @default.
• W3176037701 startingPage "3622" @default.
• W3176037701 abstract "Background Cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, are approved to treat hormone receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative advanced breast cancer (ABC) and are associated with hematologic toxicity. African American women, who are underrepresented in CDK4/6 inhibitor clinical trials, may experience worse neutropenia because of benign ethnic neutropenia. The authors specifically investigated the hematologic safety of palbociclib in African American women with HR‐positive/HER2‐negative ABC. Methods PALINA was a single‐arm, open‐label, investigator‐initiated study of palbociclib (125 mg daily; 21 days on and 7 days off) plus endocrine therapy (ET) in African American women who had HR‐positive/HER2‐negative ABC and a baseline absolute neutrophil count ≥1000/mm 3 (ClinicalTrials.gov identifier NCT02692755). The primary outcome was the proportion of patients who completed 12 months of therapy without experiencing febrile neutropenia or treatment discontinuation because of neutropenia. Single nucleotide polymorphism analysis was used to assess Duffy polymorphism status. Results Thirty‐five patients received ≥1 dose of palbociclib plus ET; 19 had a Duffy null polymorphism (cytosine/cytosine). There were no reports of febrile neutropenia or permanent study discontinuation because of neutropenia. Significantly more patients with the Duffy null versus the wild‐type variant had grade 3 and 4 neutropenia (72.2% vs 23.1%; P = .029) and required a palbociclib dose reduction (55.6% vs 7.7%; P = .008). Patients with the Duffy null versus the wild‐type variant had lower overall relative dose intensity (mean ± SD, 81.89% ± 15.87 and 95.67% ± 5.89, respectively; P = .0026) and a lower clinical benefit rate (66.7% and 84.6%, respectively). Conclusions These findings suggest that palbociclib is well tolerated in African American women with HR‐positive/HER2‐negative ABC. Duffy null status may affect the incidence of grade 3 neutropenia, dose intensity, and possibly clinical benefit." @default.
• W3176037701 created "2021-07-05" @default.
• W3176037701 creator A5002120924 @default.
• W3176037701 creator A5003348942 @default.
• W3176037701 creator A5004657497 @default.
• W3176037701 creator A5007225202 @default.
• W3176037701 creator A5016862869 @default.
• W3176037701 creator A5018790034 @default.
• W3176037701 creator A5020226884 @default.
• W3176037701 creator A5021129439 @default.
• W3176037701 creator A5022876688 @default.
• W3176037701 creator A5032189899 @default.
• W3176037701 creator A5055468527 @default.
• W3176037701 creator A5070491879 @default.
• W3176037701 creator A5071176191 @default.
• W3176037701 creator A5081490758 @default.
• W3176037701 creator A5083153495 @default.
• W3176037701 creator A5085083246 @default.
• W3176037701 date "2021-06-22" @default.
• W3176037701 modified "2023-10-17" @default.
• W3176037701 title "Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer" @default.
• W3176037701 cites W1464936406 @default.
• W3176037701 cites W2053525141 @default.
• W3176037701 cites W2097968792 @default.
• W3176037701 cites W2144390371 @default.
• W3176037701 cites W2144990191 @default.
• W3176037701 cites W2154626333 @default.
• W3176037701 cites W2155290278 @default.
• W3176037701 cites W2404884142 @default.
• W3176037701 cites W2474699717 @default.
• W3176037701 cites W2528767298 @default.
• W3176037701 cites W2552099557 @default.
• W3176037701 cites W2605489431 @default.
• W3176037701 cites W2620993107 @default.
• W3176037701 cites W2799532069 @default.
• W3176037701 cites W2805575723 @default.
• W3176037701 cites W2884436796 @default.
• W3176037701 cites W2907875659 @default.
• W3176037701 cites W2911188781 @default.
• W3176037701 cites W2950856878 @default.
• W3176037701 cites W2979291688 @default.
• W3176037701 cites W3001574063 @default.
• W3176037701 cites W4239051461 @default.
• W3176037701 doi "https://doi.org/10.1002/cncr.33620" @default.
• W3176037701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34157782" @default.
• W3176037701 hasPublicationYear "2021" @default.
• W3176037701 type Work @default.
• W3176037701 sameAs 3176037701 @default.
• W3176037701 citedByCount "7" @default.
• W3176037701 countsByYear W31760377012021 @default.
• W3176037701 countsByYear W31760377012022 @default.
• W3176037701 countsByYear W31760377012023 @default.
• W3176037701 crossrefType "journal-article" @default.
• W3176037701 hasAuthorship W3176037701A5002120924 @default.
• W3176037701 hasAuthorship W3176037701A5003348942 @default.
• W3176037701 hasAuthorship W3176037701A5004657497 @default.
• W3176037701 hasAuthorship W3176037701A5007225202 @default.
• W3176037701 hasAuthorship W3176037701A5016862869 @default.
• W3176037701 hasAuthorship W3176037701A5018790034 @default.
• W3176037701 hasAuthorship W3176037701A5020226884 @default.
• W3176037701 hasAuthorship W3176037701A5021129439 @default.
• W3176037701 hasAuthorship W3176037701A5022876688 @default.
• W3176037701 hasAuthorship W3176037701A5032189899 @default.
• W3176037701 hasAuthorship W3176037701A5055468527 @default.
• W3176037701 hasAuthorship W3176037701A5070491879 @default.
• W3176037701 hasAuthorship W3176037701A5071176191 @default.
• W3176037701 hasAuthorship W3176037701A5081490758 @default.
• W3176037701 hasAuthorship W3176037701A5083153495 @default.
• W3176037701 hasAuthorship W3176037701A5085083246 @default.
• W3176037701 hasBestOaLocation W31760377011 @default.
• W3176037701 hasConcept C121608353 @default.
• W3176037701 hasConcept C126322002 @default.
• W3176037701 hasConcept C143998085 @default.
• W3176037701 hasConcept C2775930923 @default.
• W3176037701 hasConcept C2776694085 @default.
• W3176037701 hasConcept C2777063308 @default.
• W3176037701 hasConcept C2778715236 @default.
• W3176037701 hasConcept C2778850193 @default.
• W3176037701 hasConcept C2779744173 @default.
• W3176037701 hasConcept C530470458 @default.
• W3176037701 hasConcept C71924100 @default.
• W3176037701 hasConcept C90924648 @default.
• W3176037701 hasConceptScore W3176037701C121608353 @default.
• W3176037701 hasConceptScore W3176037701C126322002 @default.
• W3176037701 hasConceptScore W3176037701C143998085 @default.
• W3176037701 hasConceptScore W3176037701C2775930923 @default.
• W3176037701 hasConceptScore W3176037701C2776694085 @default.
• W3176037701 hasConceptScore W3176037701C2777063308 @default.
• W3176037701 hasConceptScore W3176037701C2778715236 @default.
• W3176037701 hasConceptScore W3176037701C2778850193 @default.
• W3176037701 hasConceptScore W3176037701C2779744173 @default.
• W3176037701 hasConceptScore W3176037701C530470458 @default.
• W3176037701 hasConceptScore W3176037701C71924100 @default.
• W3176037701 hasConceptScore W3176037701C90924648 @default.
• W3176037701 hasFunder F4320307765 @default.
• W3176037701 hasIssue "19" @default.
• W3176037701 hasLocation W31760377011 @default.
• W3176037701 hasLocation W31760377012 @default.

• next